Uncategorized
Travoprost monotherapy for POAG reduces 24-hour IOP up to 5 years
Topical travoprost monotherapy yielded a sustained reduction in 24-hour IOP for up to 5 years in patients with primary open-angle glaucoma, according to study findings.The 5-year, prospective study included 36 patients; 34 patients completed the study.